Catabasis Pharmaceuticls Inc. (NASDAQ:CATB)’s share price traded up 3.7% during trading on Friday . The company traded as high as $3.78 and last traded at $3.63, with a volume of 69,455 shares traded. The stock had previously closed at $3.50.

A number of equities analysts have commented on the stock. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $28.00 price objective on shares of Catabasis Pharmaceuticls in a report on Wednesday, May 25th. Wedbush reaffirmed an “outperform” rating and issued a $17.00 price objective (down previously from $27.00) on shares of Catabasis Pharmaceuticls in a report on Tuesday, June 7th. Cowen and Company reaffirmed a “buy” rating on shares of Catabasis Pharmaceuticls in a report on Wednesday, June 8th. Finally, Zacks Investment Research downgraded shares of Catabasis Pharmaceuticls from a “buy” rating to a “hold” rating in a report on Monday, July 18th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Catabasis Pharmaceuticls presently has an average rating of “Buy” and an average target price of $19.05.

The stock’s 50 day moving average price is $4.17 and its 200-day moving average price is $5.17. The company’s market cap is $54.58 million.

Catabasis Pharmaceuticls (NASDAQ:CATB) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($0.61) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.03. On average, equities analysts anticipate that Catabasis Pharmaceuticls Inc. will post ($2.52) EPS for the current fiscal year.

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.